| SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES Basis of Presentation The accompanying consolidated financial statements
have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”). Principles of Consolidation The Company evaluates the need to consolidate
affiliates based on standards set forth in ASC 810 Consolidation (“ASC 810”). The consolidated financial statements include
the accounts of the Company and its subsidiaries, Piezo Motion Corp, Discovery Technology International, Inc., MemoryMD US, MemoryMD –
Russia and MemoryMD - Europe. All significant consolidated transactions and balances have been eliminated in consolidation. Use of Estimates The preparation of financial statements in accordance
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures
of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during
the reporting period. Actual results could differ from those estimates. Significant estimates include the useful life of property and
equipment and assumptions used in the valuation of options and warrants. The Effects of COVID-19 The World Health Organization (WHO) declared the
coronavirus outbreak a pandemic on January 30, 2020. Since the outbreak in China in December 2019, COVID-19 has expanded its impact to
Europe, where all of our operations reside, as well as our employees, suppliers and customers. While the disruption is currently expected
to be temporary, there is considerable uncertainty around the duration of the closings and shelter-in-place orders and the ultimate impact
of governmental initiatives. However, the financial impact and duration cannot be reasonably estimated at this time. Cash and Cash Equivalents The Company considers all highly liquid temporary
cash investments with an original maturity of three months or less to be cash equivalents. At March 31, 2022 and December 31, 2021, the
Company had no cash equivalents. The Company’s cash is held with financial
institutions, and the account balances may, at times, exceed the Federal Deposit Insurance Corporation (FDIC) insurance limit. Accounts
are insured by the FDIC up to $250,000 per financial institution. The Company has not experienced any losses in such accounts with these
financial institutions. As of March 31, 2022, and December 31, 2021, the Company had $0 and $277,989, respectively, in excess over the
FDIC insurance limit. I nventory Inventory consists of finished goods that are
valued at lower of cost or market using the weighted average method. Property and Equipment Property, plant and equipment are carried at cost.
Depreciation is provided on the straight-line method over the assets estimated service lives. Expenditures for maintenance and repairs
are charged to expense in the period in which they are incurred, and betterments are capitalized. The cost of assets sold or abandoned
and the related accumulated depreciation are eliminated from the accounts and any gains or losses are reflected in the accompanying statements
of operations of the respective period. The estimated useful lives range from 3 to 7 years. Intangible assets, net Intangible assets are measured at cost less accumulated
amortization and impairment losses, if any. Intangible assets are amortized on a straight-line
basis over their estimated useful lives, which do not exceed the contractual period, if any. The estimated useful lives, residual values,
and amortization methods are reviewed at each year end, and any changes in estimates are accounted for prospectively.
Patents 3-15 years
Licenses and trademarks 9 years
Customer relationships 13 years Amortization expense is included in the consolidated
income statement within general and administrative expenses. The asset is tested for impairment if there is
a trigger for impairment. Goodwill Goodwill represents the excess of the consideration
transferred over the fair value of the net identifiable assets acquired. Goodwill is evaluated for impairment annually or whenever we
identify certain triggering events or circumstances that would more likely than not reduce the fair value of a reporting unit below its
carrying amount. Events or circumstances that might indicate an interim evaluation is warranted include, among other things, unexpected
adverse business conditions, macro and reporting unit specific economic factors (for example, interest rate and foreign exchange rate
fluctuations, and loss of key personnel), supply costs, unanticipated competitive activities, and acts by governments and courts. Convertible Notes Payable The Company has issued convertible notes, which
contain variable conversion features, whereby the outstanding principal and accrued interest automatically convert into common shares
at a fixed price which may be at a discount to the common stock at the time of conversion. For certain notes, the conversion features
are contingent upon future events, whereby, the holder agreed not to convert until the contingent future event has occurred. Revenue Recognition On January 1, 2018, the Company adopted ASC Topic
606 Revenue from Contracts with Customers. This guidance requires an entity to recognize revenue by applying the following steps:
(1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price;
(4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation
is satisfied. Once the steps are met, revenue is recognized, generally upon receiving a letter of acceptance from the customer. There
has been no material effect on the Company’s financial statements as a result of adopting Topic 606. The Company recognizes revenue from the sale of
NeuroCaps, as well as revenue from the sale of goods purchased through manufacturers of medical devices. Primarily all revenues for the
three months ended March 31, 2022 are from the sale of medical devices purchased from Neurotech, a related party. Revenues for the three
months ended March 31, 2021 of $1,475 related to the sales of evaluation kits. Research and Development Costs The Company expenses all research and development
costs as they are incurred. Research and development includes expenditures in connection with in-house research and development salaries
and staff costs, application and filing for regulatory approval of proposed products, regulatory and scientific consulting fees, as well
as contract research, data collection, and monitoring, related to the research and development of the cloud infrastructure, data imaging,
and proprietary products and technology. Research and development costs recognized in the statement of operations for the three months
ended March 31, 2022 and 2021 were $84,717 and $55,165, respectively. Sales and Marketing Advertising and marketing costs are expensed as
incurred. Advertising and marketing costs recognized in the statement of operations for the three months ended March 31, 2022 and 2021
were $191,471 and $43,773, respectively. Stock-based Compensation The Company measures and recognizes compensation
expense for all stock-based payments at fair value over the requisite service period. The Company uses the Black-Scholes option pricing
model to determine the weighted average fair value of options and warrants. Equity-based compensation expense is recorded in administrative
expenses based on the classification of the employee or vendor. The determination of fair value of stock-based payment awards on the date
of grant using an option-pricing model is affected by our stock price as well as by assumptions regarding a number of subjective variables.
These variables include, but are not limited to, the expected stock price volatility over the term of the awards, and actual and projected
employee stock option exercise behaviors. Basic and Diluted Net Loss Per Common Share Basic net loss per share is computed by dividing
the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed
by dividing the net loss by the weighted average number of common shares outstanding for the period and, if dilutive, potential common
shares outstanding during the period. Potentially dilutive securities consist of the incremental common shares issuable upon exercise
of common stock equivalents such as stock options, warrants and convertible debt instruments. Potentially dilutive securities are excluded
from the computation if their effect is anti-dilutive. As a result, the basic and diluted per share amounts for all periods presented
are identical. In the three months ended March 31, 2022 and 2021, 73,193,185, and 0 anti-dilutive securities were excluded from the computation,
respectively. Fair Value of Financial Instruments The Company’s financial instruments are
measured and recorded at fair value based on inputs and assumptions that market participants would use in pricing an asset or a liability.
Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date. When determining fair value, management considers the principal or most advantageous
market in which the Company would transact, and also considers assumptions that market participants would use when pricing the asset or
liability, such as inherent risk, transfer restrictions, and risk of non-performance. Fair value is determined for assets and liabilities
using a three-tiered value hierarchy into which these assets and liabilities are grouped based upon significant inputs as follows:
● Level 1 - Quoted prices in active markets for identical assets or liabilities.
● Level 2 - Observable inputs, other than Level 1 prices, such as quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.
● Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. When a determination is made to classify a financial instrument within Level 3, the determination is based upon the lack of significance of the observable parameters to the overall fair value measurement. However, the fair value determination for Level 3 financial instruments may consider some observable market inputs. The lowest level of significant input determines
the placement of the entire fair value measurement in the hierarchy. The carrying values of cash, prepaid expenses and other current assets,
convertible notes, accounts payable, loans payable and due to others approximate fair value due to the short-term nature of these items. The Company did not have any other Level 1, Level
2 or Level 3 assets or liabilities as of March 31, 2022 and December 31, 2021. Income Taxes The Company accounts for income taxes using the
asset-and-liability method in accordance with ASC Topic 740, “Income Taxes”. Deferred tax assets and liabilities are recognized
for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities
and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using
enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or
settled. The effect on the deferred tax assets and liabilities of a change in tax rate is recognized in the period that includes the enactment
date. A valuation allowance is recorded if it is more-likely-than-not that some portion or all of the deferred tax assets will not be
realized in future periods. The Company follows the guidance in ASC Topic
740-10 in assessing uncertain tax positions. The standard applies to all tax positions and clarifies the recognition of tax benefits in
the financial statements by providing for a two-step approach of recognition and measurement. The first step involves assessing whether
the tax position is more-likely-than-not to be sustained upon examination based upon its technical merits. The second step involves measurement
of the amount to be recognized. Tax positions that meet the more-likely-than-not threshold are measured at the largest amount of tax benefit
that is greater than 50% likely of being realized upon ultimate finalization with the taxing authority. The Company recognizes the impact
of an uncertain income tax position in the financial statements if it believes that the position is more likely than not to be sustained
by the relevant taxing authority. The Company will recognize interest and penalties related to tax positions in income tax expense. As
of March 31, 2022, and December 31, 2021, the Company had no unrecognized uncertain income tax positions. Reclassification Certain prior years balances have been reclassified to conform to current
year presentation. Recently Issued Accounting Pronouncements From time to time, new accounting pronouncements
are issued by the Financial Accounting Standard Board (“FASB”) or other standard setting bodies that the Company adopts as
of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards
that are not yet effective will have a material impact on the Company’s financial position or results of operations upon adoption. |
